IC Weekender: UK pharma giants, a high-risk portfolio & more


The UK’s three pharma giants GlaxoSmithKline, Shire and AstraZeneca have not given investors much cause for celebration in recent months and the outlook isn’t particularly encouraging, says Megan Boxall. Click here to read the latest on a sector in need of a tonic.

In this week's portfolio clinic, our experts reckon our reader's portfolio is quite high risk, so he should consider some safer assets. Click here to read what Chris Dillow and our guest experts suggest.

Elsewhere and after going to press this week, we had a flurry of company news with U+I proving its doubters wrong, plus the latest from Morses ClubPhoenix Spree Deutschland and ULS Technology. There was also an exclusive on Polymetal from Alex Newman, as the Russian company's CEO may soon push for a long-term move into rare earth minerals. 

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now